National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$45.00
add to cart

Rights & Permissions

topleft topright

Improving Palliative Care for Cancer (2001)
Institute of Medicine (IOM)

Citation Manager

. "1 Background and Recommendations." Improving Palliative Care for Cancer. Washington, DC: The National Academies Press, 2001.

Please select a format:

BibTeX EndNote RefMan


Page
34
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Improving Palliative Care for Cancer

TABLE 1-3 Symptom Control Research Opportunities and Unmet Needs

Symptom

Basic

Clinical or Health Services

Pain

• Elucidate basic mechanisms of visceral and neuropathic pain; identify new treatments

• Identify modifications of nervous system involved in chronic pain perception

• Find new compounds with more precise analgesic action and fewer side effects

• Find molecular basis of pain signaling, receptor modification due to pain, and ways to modify

• Identify forebrain structures that modulate responses to “painful” signals

• Determine receptor affinities of different opioids

• Determine why so many patients have poorly controlled pain

• Study ways to improve cancer pain management

• Determine effectiveness of treatments for neuropathic pain

• Determine effects of cancer on tolerance to opioid analgesics and how pain can be managed in already tolerant patients

• Determine side-effect profiles of different opioids

• Conduct trials of intrathecal delivery of novel analgesics

Anorexia or Cachexia

• Elucidate roles for various cytokines in cachexia

• Elucidate roles of food regulatory peptides in cachexia

Conduct clinical trials of

• Proinflammatory mediators

• Appetite stimulants

• Anticatabolic agents (e.g., neuropeptide agonists or antagonists, beta2-adrenoceptor agonists)

• Polyunsaturated fatty acids, n-3 fatty acids, fish oil

• Anabolic agents (especially hormonal)

• Anticytokines (e.g., megestrol acetate, medroxyprogesterone acetate, thalidomide, melatonin)

Cognitive failure: delirium, temporary and permanent cognitive impairment

• Elucidate underlying mechanisms of delirium and cognitive impairment

• Identify role of cancer disease process in cognitive impairment

• Determine how biological therapies (e.g., interferon alpha, interleukin-2) produce cognitive impairment

• Find biological markers for patients most at risk of

• Develop standardized assessment for delirium

• Determine prevalence, nature, and current treatments for delirium and cognitive impairment

• Conduct clinical trials of

– Drugs used empirically for delirium (haloperidol) and cognitive impairment (methylphenidate)

– stimulants for cognitive

Page
34